Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program

Ramaswamy Govindan, Ronald Natale, James Wade, Roy Herbst, Annetta Krebs, Richard Reiling, Thomas Hensing, Antoinette Wozniak, Chandra Belani, Karen Kelly, Judith Ochs

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Chemotherapy (CT) is recommended in numerous clinical guidelines for advanced non-small cell lung cancer (NSCLC) and offers improved survival over best supportive care. However, many patients with advanced NSCLC never receive CT because of advanced age, poor performance status, comorbidities, or patient refusal. The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib has shown antitumor activity and a favorable toxicity profile in pretreated patients with recurrent advanced NSCLC and was made available in a worldwide Expanded Access Program (EAP) to >37,000 patients who did not respond to standard treatment or were ineligible for or refused CT. A retrospective chart review of 1671 consecutive patients enrolled at 11 sites in the US arm of the EAP identified 198 patients with advanced NSCLC who had not received previous CT. All patients were treated with gefitinib 250 mg/d until treatment failure or toxicity occurred. Patients were treated for a mean of 4.7 months. The most common adverse events were diarrhea (31.3%) and rash (31.3%). Complete and partial response rates were 0.7 and 5.6%, respectively, and 40.6% had stable disease. Median survival was 6 months, and estimated 1-year survival was 29.7%. The majority of patients did not receive subsequent CT.

Original languageEnglish (US)
Pages (from-to)331-337
Number of pages7
JournalLung Cancer
Volume53
Issue number3
DOIs
StatePublished - Sep 1 2006

Fingerprint

Non-Small Cell Lung Carcinoma
Safety
Drug Therapy
Survival
gefitinib
Exanthema
Treatment Failure
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Comorbidity
Diarrhea
Guidelines

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Govindan, Ramaswamy ; Natale, Ronald ; Wade, James ; Herbst, Roy ; Krebs, Annetta ; Reiling, Richard ; Hensing, Thomas ; Wozniak, Antoinette ; Belani, Chandra ; Kelly, Karen ; Ochs, Judith. / Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program. In: Lung Cancer. 2006 ; Vol. 53, No. 3. pp. 331-337.
@article{0f34ecb795044eda806330fe9eab94a1,
title = "Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program",
abstract = "Chemotherapy (CT) is recommended in numerous clinical guidelines for advanced non-small cell lung cancer (NSCLC) and offers improved survival over best supportive care. However, many patients with advanced NSCLC never receive CT because of advanced age, poor performance status, comorbidities, or patient refusal. The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib has shown antitumor activity and a favorable toxicity profile in pretreated patients with recurrent advanced NSCLC and was made available in a worldwide Expanded Access Program (EAP) to >37,000 patients who did not respond to standard treatment or were ineligible for or refused CT. A retrospective chart review of 1671 consecutive patients enrolled at 11 sites in the US arm of the EAP identified 198 patients with advanced NSCLC who had not received previous CT. All patients were treated with gefitinib 250 mg/d until treatment failure or toxicity occurred. Patients were treated for a mean of 4.7 months. The most common adverse events were diarrhea (31.3{\%}) and rash (31.3{\%}). Complete and partial response rates were 0.7 and 5.6{\%}, respectively, and 40.6{\%} had stable disease. Median survival was 6 months, and estimated 1-year survival was 29.7{\%}. The majority of patients did not receive subsequent CT.",
author = "Ramaswamy Govindan and Ronald Natale and James Wade and Roy Herbst and Annetta Krebs and Richard Reiling and Thomas Hensing and Antoinette Wozniak and Chandra Belani and Karen Kelly and Judith Ochs",
year = "2006",
month = "9",
day = "1",
doi = "10.1016/j.lungcan.2006.04.013",
language = "English (US)",
volume = "53",
pages = "331--337",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

Govindan, R, Natale, R, Wade, J, Herbst, R, Krebs, A, Reiling, R, Hensing, T, Wozniak, A, Belani, C, Kelly, K & Ochs, J 2006, 'Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program', Lung Cancer, vol. 53, no. 3, pp. 331-337. https://doi.org/10.1016/j.lungcan.2006.04.013

Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program. / Govindan, Ramaswamy; Natale, Ronald; Wade, James; Herbst, Roy; Krebs, Annetta; Reiling, Richard; Hensing, Thomas; Wozniak, Antoinette; Belani, Chandra; Kelly, Karen; Ochs, Judith.

In: Lung Cancer, Vol. 53, No. 3, 01.09.2006, p. 331-337.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program

AU - Govindan, Ramaswamy

AU - Natale, Ronald

AU - Wade, James

AU - Herbst, Roy

AU - Krebs, Annetta

AU - Reiling, Richard

AU - Hensing, Thomas

AU - Wozniak, Antoinette

AU - Belani, Chandra

AU - Kelly, Karen

AU - Ochs, Judith

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Chemotherapy (CT) is recommended in numerous clinical guidelines for advanced non-small cell lung cancer (NSCLC) and offers improved survival over best supportive care. However, many patients with advanced NSCLC never receive CT because of advanced age, poor performance status, comorbidities, or patient refusal. The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib has shown antitumor activity and a favorable toxicity profile in pretreated patients with recurrent advanced NSCLC and was made available in a worldwide Expanded Access Program (EAP) to >37,000 patients who did not respond to standard treatment or were ineligible for or refused CT. A retrospective chart review of 1671 consecutive patients enrolled at 11 sites in the US arm of the EAP identified 198 patients with advanced NSCLC who had not received previous CT. All patients were treated with gefitinib 250 mg/d until treatment failure or toxicity occurred. Patients were treated for a mean of 4.7 months. The most common adverse events were diarrhea (31.3%) and rash (31.3%). Complete and partial response rates were 0.7 and 5.6%, respectively, and 40.6% had stable disease. Median survival was 6 months, and estimated 1-year survival was 29.7%. The majority of patients did not receive subsequent CT.

AB - Chemotherapy (CT) is recommended in numerous clinical guidelines for advanced non-small cell lung cancer (NSCLC) and offers improved survival over best supportive care. However, many patients with advanced NSCLC never receive CT because of advanced age, poor performance status, comorbidities, or patient refusal. The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib has shown antitumor activity and a favorable toxicity profile in pretreated patients with recurrent advanced NSCLC and was made available in a worldwide Expanded Access Program (EAP) to >37,000 patients who did not respond to standard treatment or were ineligible for or refused CT. A retrospective chart review of 1671 consecutive patients enrolled at 11 sites in the US arm of the EAP identified 198 patients with advanced NSCLC who had not received previous CT. All patients were treated with gefitinib 250 mg/d until treatment failure or toxicity occurred. Patients were treated for a mean of 4.7 months. The most common adverse events were diarrhea (31.3%) and rash (31.3%). Complete and partial response rates were 0.7 and 5.6%, respectively, and 40.6% had stable disease. Median survival was 6 months, and estimated 1-year survival was 29.7%. The majority of patients did not receive subsequent CT.

UR - http://www.scopus.com/inward/record.url?scp=33746897725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746897725&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2006.04.013

DO - 10.1016/j.lungcan.2006.04.013

M3 - Article

C2 - 16797779

AN - SCOPUS:33746897725

VL - 53

SP - 331

EP - 337

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -